What is claimed is:
1. A method for enriching for neural stem cells or a more restricted subset of progenitors, comprising:
identifying cells with at least one positive or negative neural stem cell-specific markers from a population of cells; and
enriching for said cells with said at least one positive or negative neural stem cell-specific markers.
2. The method of claim 1, wherein said positive or negative neural stem cell markers are selected from the group consisting of: proteinaceous or nonproteinaceous markers.
3. The method of claim 2, wherein said positive neural stem cell markers are proteinaceous and are selected from the group consisting of: CD9, CD15, CD95, CD3, MHC 1 and b2 microglobulin.
4. The method of claim 2, wherein said negative neural stem cell markers are proteinaceous and are selected from the group consisting of: MHC class II, HLA-DR, Glycophorin-A, CD3, CD5, CD7, CD10, CD11b, CD13, CD14, CD16, CD19, CD20, CD22, CD23, CD25, CD31, CD33, CD41, CD45, CD54, CD80, CD83, CD86, TAPA-1, CD15, CD95, CD9, MHC classI, 2 microglobulin, CD8, CD34, CD38, CD56, CD81, and CD152.CD133, CD117, CD154.
5. The method of claim 2 wherein said positive neural stem cell marker is ganglioside GD2 and rarely GD3 under selective circumstances.
6. The method of claim 1 wherein said enriching for cell with neural stem cell-specific markers is by cell sorting.
7. The method of claim 1 wherein said enriching for cells with neural stem cell-specific markers by at least one affinity column.
8. The method of claim 1, wherein said population of cells is from a tissue selected from the group consisting of: the brain, the spinal cord, the retina, and fetal tissue.
9. The method of claim 8, wherein said brain and retina are adult brain and retina.
10. An enriched neuronal stem cell population enriched by the method of claim 1.
11. A method of enriching for retinal stem cells, comprising:
identifying cells which express the GD2 gangliosidic marker from a population of cells; and
enriching for said cells which express the GD2 gangliosidic marker.
12. The method of claim 11 wherein said population of cells is retinal tissue and fetal tissue.
13. A method of testing for drugs which are agonists or antagonists of neural stem cells.
14. A method for diagnosing and identifying neural tumors, comprising:
identifying whether cells from said neural tumors express positive or negative neural stem cell markers.
15. The method of claim 14, wherein said positive neural stem cell markers are selected from the group consisting of, Ganglioside GD2, TAPA-1, CD15, CD95, CD9, MHC classI, 2 microglobulin, CD8, CD34, CD38, CD56, CD81, and CD152.
16. The method of claim 14, wherein said negative neural stem cell markers are selected from the group consisting of; MHC class II, HLA-DR, Glycophorin-A, GD3, CD3, CD5, CD7, CD10, CD11b, CD13, CD14, CD16, CD19, CD20, CD22, CD23, CD25, CD31, CD33, CD41, CD45, CD54, CD80, CD83, CD86, CD133, CD117, CD154.
17. A method for controlling excessive proliferation of neural transplants, comprising:
administering an agent which reduces the proliferation of neural transplant cells selected from the group consisting of: antibodies to neural stem cell markers, antisense oligonucleotides for neural stem cell markers, and antagonists of neural stem cell markers.
18. The method of claim 17, wherein said neural stem cell markers are selected from the group consisting of: GD2, TAPA-1, CD15, CD95, CD9, and CD15.
19. A method for treating neural tumors, comprising:
administering an agent which reduces the proliferation of neural transplant cells selected from the group consisting of: antibodies to neural stem cell markers, antisense oligonucleotides for neural stem cell markers, and antagonists of neural stem cell markers.
20. The method of claim 19, wherein said neural stem cell markers are selected from the group consisting of: GD2, TAPA-1, and CD15.
21. A method for the isolation of NSCs comprising:
isolating tissue from a mammalian subject;
treating said cells with an MHC-inducing agent; and
identifying cells which express MHC markers andor peptides of internal cellular markers of NSCs.
22. The method of claim 21, wherein said internal cellular markers of NSCs are selected from the group consisting of: Nestin, MASH I, and MSH I.
23. A method for the isolation of RSCs comprising:
isolating tissue from a mammalian subject;
treating said cells with an MHC-inducing agent; and
identifying cells which express MHC markers andor peptides of internal cellular markers of RSCs.
The claims below are in addition to those above.
All refrences to claim(s) which appear below refer to the numbering after this setence.
1. An article comprising a cured coating, the cured coating comprises the dried reaction product of a coating composition comprising:
a solvent;
a polymerizable resin composition;
a non-ionic unpolymerizable surfactant in combination with a polymerizable surfactant, the surfactants having an hydrophilic lipophilic balance ranging from 2 to 6; wherein the total amount of the surfactants is greater than 10 wt-% and ranges up to 25 wt-% solids; and
an additive comprising a fluorinated group, a hydrophobic group, and poly (meth) acrylate linkages;
wherein the cured coating comprises a plurality of pores wherein a portion of the pores are interconnected and comprise the non-ionic unpolymerizable surfactant optionally in combination with the polymerizable surfactant.
2. The article of claim 1 wherein the hydrophobic group comprises an alkyl or alkylene group having greater than 6 carbon atoms.
3. The article of claim 1 wherein the unpolymerizable non-ionic surfactant is a liquid at ambient temperature.
4. The article of claim 1 wherein the unpolymerizable non-ionic surfactant comprises an alkyl or alkenyl group having at least 12 carbon atoms.
5. The article of claim 2 wherein the additive further comprises ethoxylate repeat units, propoxylate repeat units, or a mixture thereof bonded to the hydrophobic group.
6. The article of claim 2 wherein the additive is a free-radically polymerizable additive.
7. The article of claim 2 wherein the coating composition further comprises an additive comprising a polydimethylsiloxane backbone and at least one alkoxy side chain terminating with a (meth) acrylate group.
8. The article of claim 1 wherein the polymerizable resin composition comprises at least one free-radically polymerizable monomer, oligomer, polymer, or mixture thereof.
9. The article of claim 1 wherein the coating composition further comprises inorganic oxide nanoparticles.
10. The article of claim 1 wherein the cured coating exhibits a ratio of simulated fingerprint visibility at 20 minutes to initial simulated fingerprint of less than 0.80.
11. The article of claim 1 wherein the article is an optical display.
12. The article of claim 1 wherein the cured coating is provided on a light transmissive polymeric film.
13. The article of claim 1 wherein the additive has the formula:
Rf is a monovalent perfluoropolyether group,
Q is a connecting group having a valency of at least 2,
X is O, S, or NR, where R is H or lower alkyl of 1 to 4 carbon atoms,
R6 is hydrogen or alkyl having from 1 to 4 carbon atoms,
R is a hydrophobic group,
Ra is independently an alkylene group CxH2x where x =2 to 4,
j ranges from 7 to 50,
A is a (meth) acryl functional group, \u2014XC(O)C(R2)\u2550CH2, where R2 is a lower alkyl of 1 to 4 carbon atoms or H or F,
a ranges from 1 to 6,
m, n and o each independently range from 1 to 100, and
p ranges from 1 to 50.
14. The article of claim 1 wherein the additive has the formula:
Rf is a monovalent perfluoropolyether group,
Q is a connecting group having a valency of at least 2,
X is O, S, or NR, where R is H or lower alkyl of 1 to 4 carbon atoms,
R6 is hydrogen or alkyl having from 1 to 4 carbon atoms,
R is a hydrophobic group,
Ra is independently an alkylene group CxH2x where x =2 to 4,
j ranges from 7 to 50,
R4 is an alky group having 1-24 carbon atoms,
A is a (meth) acryl functional group, \u2014XC(O)C(R2)\u2550CH2, where R2 is a lower alkyl of 1 to 4 carbon atoms or H or F,
a ranges from 1 to 6,
m, n and o each independently range from 1 to 100, and
p ranges from 0 to 50.
15. The article of claim 14 wherein p is at least 1.